Introduction &
Today, obesity has reached epidemic proportions in western populations and is a major burden for health care systems worldwide. The etiology of obesity is complex, and seems to be based on both environmental and multiple genetic factors. Heritability of obesity is high and genetic factors contribute 40 -70 % to the development of obesity [1, 2] . Therefore, it is not surprising that enormous eff orts have been made during the last years in order to identify obesity-associated gene candidates. Recent genome wide association studies (GWAS) were successful in identifying common risk loci associated with obesity ( Table 1 ) . One of the fi rst studies in this fi eld showed data concerning the role of FTO (fat mass and obesity associated) in the development of type 2 diabetes mellitus (T2DM) [3] . A common variant located in the fi rst intron of this gene (rs9939609) showed signifi cant association with T2DM. Interestingly, after adjustment for body mass index (BMI), this eff ect was completely abolished, suggesting an FTO -type 2 diabetes association through BMI. Homozygous carriers of the risk allele were in average ~ 3 kg heavier and had a 1.67-fold increased risk of obesity compared to control persons [3] . These fi ndings have been replicated in 13 cohorts including more then 38 000 individuals. Another study showed an association of a FTO gene variant (rs9930506) with obesity in Sardinians. This fi nding has been replicated in Europeans and Hispanic Americans [4] .
Fat mass and obesity associated gene ( FTO ) is the most relevant polygene for obesity to date. It has been identifi ed by genome wide association studies concerning body weight regulation. However, its functional relevance for the pathogenesis of obesity remains elusive. Studies in rodents provide data pointing to a central role of FTO through regulation of food intake. In addition, peripheral eff ects of FTO are also discussed in the literature. This review highlights the possible relevance of FTO for weight regulation and obesity development in central and peripheral tissues with a special focus on adipose tissue. twin study including more than 7 000 children, the association between the rs9939609 FTO gene variant and BMI increases from the age of 4 to age 11 [19] , showing a clear time-dependency. This association seems to decline in later life, shown by a longitudinal analysis with > 5 000 participants [17] . However, these changes are not signifi cant. To date, the association between FTO and obesity has been replicated robustly. FTO variants were linked to obesity-related factors such as body weight [4, 20, 21] , type 2 diabetes [7, 22] , leptin levels [21] , subcutaneous fatness [3, 20] , fat mass [3, 20, 21] , hip [4] , and waist [21] circumference as well as to mortality [23] . The fact that FTO plays an essential role in the pathogenesis of obesity is further emphasised by recent knock-out studies [24] . Nevertheless, the functional properties of FTO and its encoded protein remain poorly understood.
Properties of FTO &
FTO is a large gene with more than 4 000 kb and 9 exons and is located on the chromosome 16q12.2 of the human genome ( • ▶ Fig. 1 ). Its murine homologue Fto was fi rst identifi ed as part of a 1.6-megabase (Mb) deletion on chromosome 8 in the Fused toes mutant. The deletion includes not only Fto , but also Ftm , Ftl and the Iroquois B cluster consisting of Irx3 , 5 , and 6 [25, 26] . Fused toes mutants show severe developmental defects. Homozygotes are embryonically lethal and show left-right asymmetry, polydactyly, and defects in hypothalamus development [27 -29] . Heterozygous mice have fused digits and hyperplasia of the thymus, possibly due to a suppression of apoptosis [30] In humans, a loss-of-function mutation in the FTO gene causes an autosomal-recessive lethal syndrome. The aff ected subjects suff er from postnatal growth retardation and severe developmental defects such as microencephaly, functional brain defects, facial dysmorphisms and severe psychomotor delay. In several cases, cardiac defects and genital abnormalities are also apparent. This indicates that FTO is essential for normal development in humans [32] . FTO is ubiquitously expressed in human and animal tissues [3, 33] with high abundance in the brain and skeletal muscle. Bioinformatic analyses suggest that FTO belongs to the superfamily of Fe(II)-and 2-oxoglutarate-dependent dioxygenases [34, 35] . Members of this family are involved in the posttranslational modifi cation of proteins, DNA repair, and fatty acid metabolism [36] . In vitro, recombinant murine Fto catalyses the Fe(II)-and 2-oxoglutarate-dependent demethylation of 3-methylthymine and 3-methyluracil in single-stranded DNA and RNA [34, 37] , and is therefore suggested to be involved in RNA repair and gene regulation [37] . In transfected cells, an YFP-FTO fusion protein localises to the nucleus, pointing to its potential role in nucleic acid demethylation [31, 34] . Interestingly, newborns homozygous for a FTO risk allele show decreased levels of methylation of the PPARGC1A gene [38] . Mass spectrometry analyses indicate that FTO exists in both monomeric and dimeric forms and identifi ed the putative c-terminal dimerisation domain [31] . Whether dimerisation of FTO protein is needed for its catalytic activity is not yet fully elucidated.
Central Nervous Eff ects &
Weight gain in subjects carrying FTO risk variants may be based on central nervous eff ects of FTO . If FTO regulates weight gain via the central nervous system, it might modulate energy balance, eating behaviour, or physical activity. In a study concerning the eating behaviour of children, the risk variant of rs9939609 is coupled to an increased energy intake without aff ecting resting energy expenditure [39] . These data have been confi rmed by investigations concerning eating behaviour of UK children. Children with the risk variant of rs9939609 show a diminished sa tiety, a higher enjoyment of food [40] , and higher food intake in the absence of hunger [41] . Additionally, no association between FTO and resting energy expenditure or physical activity can be shown in adolescents [42] . This is contradictory to the fact that Fto − / − mice show a reduced body weight because of an increased energy expenditure in presence of increased sympathic activation in combination with higher food intake [24] . In Fto I367F mice, resting energy expenditure is also increased, but animals do not exhibit a higher food intake [31] . FTO is highly expressed in the hypothalamus, an area which plays an essential role in energy homeostasis and appetite regulation. For rodents, several investigators show a nutritionally mediated regulation in FTO mRNA expression in the arcuate nucleus, an area with NPY-containing neurons which regulate appetite. However, the direction of Fto regulation is diff erent between mice and rats [33, 34, 43] . In rats starved for 48 h, hypothalamic Fto mRNA expression is reduced by 60 % . This eff ect is not abolished by leptin supplementation, which was given in order to exclude expression changes due to low leptin levels that occur during starvation [34] . In contrast, food deprivation for 48 h and food restriction to 45 % for 12 days in mice leads to an upregulation of Fto mRNA levels by 41 and 27 % , respectively. The reasons for this discrepancy remain speculative so far.
A relatively new concept in obesity research is the model of human cerebrocortical insulin resistance [44] . In lean subjects, spontaneous cortical activity is increased by insulin treatment, while this eff ect is absent in obese persons. Interestingly, the FTO obesity risk variant rs8050136 is associated with a reduced insulin eff ect on beta activity in a study group with 720 obese persons and lean controls [45] . These eff ects are also sustained after matching with BMI, indicating that reduction in cerebrocortical insulin sensitivity might also contribute to the mechanisms by which FTO variants infl uence the pathogenesis of obesity.
Peripheral Eff ects &
Besides its central eff ects on energy regulation, FTO probably has direct eff ects on the regulation of peripheral organ functions involved in the development of obesity and obesity related comorbidities, such as in skeletal muscle, liver, and adipose tissue. In addition to expression in the brain, FTO is also highly expressed in the skeletal muscle [3] . Homozygous carriers of the FTO rs9939609 risk variant show a faster recovery rate of phosphocreatine and inorganic phosphate in skeletal muscle [46] , which indicates an enhanced mitochondrial oxidative phosphorylation. The authors conclude that an increased energy effi ciency in oxidative muscle fi bres after exercise might contribute to the increased risk of obesity and T2DM. There is no association between the FTO genotype and FTO mRNA expression in muscle. Also, expression of UCP2 and UCP3, as well as genes involved in oxidative phosphorylation are not associated with the FTO genotype. Additionally, persons homozygous for the risk variant have signifi cant higher hepatic insulin resistance levels and elevated fasting blood glucose than control subjects [46] . This eff ect has also been shown in Fto − / − mice, which display improved hepatic insulin sensitivity on the level of Akt [24] . However, skeletal muscle insulin sensitivity is not aff ected by FTO expression or polymorphisms in men or mice [24, 46] .
FTO is also regulated in cells of the immune system. In mouse macrophages stimulated with IFN-gamma and LPS, FTO mRNA is induced by about 15-fold [17] . Granted that obesity is coupled to a state of chronic infl ammation in the adipose tissue [47] , FTO might be a link between metabolism and infl ammation in the pathogenesis of obesity.
FTO and Fat Mass &
Adipose tissue is not only a repository of energy but is also recognised as an endocrine organ. By releasing a vast number of hormones and other factors, it contributes to the development of obesity-related co-morbidities [48] .The expression of FTO in adipose tissue is relatively low compared to the brain [3] , but the role of the adipocyte in obesity is undisputable. After 12 weeks of high fat feeding, weight gain and fat accumulation in male Fto + / − and Fto − / − mice is signifi cantly reduced compared to wt mice [24] . Fto I367F mice share several phenotypical aspects with the Fto knock-out model [31] . In general, alterations in body and fat mass are lower compared to knock-out mice, probably due to remaining functional activity of the mutated protein. On a high fat diet for 24 weeks, fat mass of Fto I367F animals is reduced, while lean mass increases. Gene expression analyses of WAT revealed a decrease in the expression of genes involved in infl ammation. At the same time, genes of the fat metabolism were altered. In mice, FTO shows diff erent expression patterns in diff erent adipose depots: The highest expression is found in the mesenteric fat, where it is expressed by two-fold higher than in subcutaneous fat [33] . , Fto expression is signifi cantly reduced in mesenteric fat depots compared to control mice [17, 33] , whereas diet induced obesity does not cause a change of regulation of Fto . In control mice, Fto expression is signifi cantly higher in the stromavascular fraction of the epididymal fat depot compared to isolated adipocytes from the same depot [33] . In humans, Kl ö ting et al. investigated the fat depot specifi city of FTO and its association with BMI in adipose tissue of 55 lean and obese patients [49] . Here, FTO shows a three-fold higher expression in subcutaneous fat compared to the visceral depot. Additionally, subcutaneous and visceral FTO mRNA levels are signifi cantly correlated. Visceral FTO expression is negatively correlated with BMI and fat mass, but not with visceral fat area. Subcutaneous FTO mRNA is negatively correlated with BMI, fat mass, subcutaneous fat area and leptin. After correction for sex and age, the correlation between subcutaneous FTO mRNA and BMI abolishes, whereas the correlation in the visceral depot remains. In this study, no correlation between FTO mRNA in fat depots and markers of insulin sensitivity and altered glucose metabolism could be shown [49] . All patients have been genotyped for the FTO gene variant rs8050136, which lies in linkage disequilibrium with rs9939609. No association between this SNP and FTO mRNA was detected in both subcutaneous and visceral tissues [49] . In a study investigating lipolytic eff ects in in vitro diff erentiated adipocytes, persons with the FTO risk allele show lower basal lipolytic activity in cells of subcutaneous adipose tissue [50] . This peripheral eff ect of the FTO risk allele might contribute to the association with BMI and fat mass. In this study obese patients display increased mRNA levels of FTO , whereas no difference between fat depots can be shown. Additionally, in in vitro studies using isolated primary human preadipocytes FTO mRNA levels are downregulated during adipocyte diff erentiation. The authors claim a protective eff ect of lipolysis on the accumulation of excess body fat [50] . However, the molecular mechanisms of the lipolysis regulation by FTO need to be defi ned.
Perspectives &
The association between variants in the FTO gene and obesity is now widely accepted. We wait for answers to the remaining questions concerning the role of FTO in the pathogenesis of obesity. FTO displays activity in the central nervous system by infl uencing energy expenditure and food intake. However, the fi ndings in mouse models and humans are contradictory. In humans FTO seems to regulate body mass by infl uencing food intake, while mice display alterations in the energy expenditure. The metabolic pathways by which FTO polymorphisms lead to an altered behaviour and energy metabolism need to be unravelled in further studies. Additionally, it will be answered if mouse models and humans are comparable concerning FTO regulation. In peripheral tissues, FTO is involved in adipocyte lipolysis, skeletal muscle energy effi ciency and hepatic glucose metabolism. On the basis of fi ndings in knock-out experiments, FTO seems to be a key factor in weight gain and obesity. FTO is downregulated in adipocytes during diff erentiation and in adipose tissue of obese persons. On the other hand, FTO knock-out and loss-offunction mutation in mice leads to a suppression of fat gain. Additionally, FTO is expressed higher in stromavascular cells of the adipose tissue than adipocytes. This might be a hint that FTO is involved in regulating adipogenesis or lipid accumulation. It would be interesting to identify the key polymorphisms that confer susceptibility to obesity and to reveal the molecular mechanisms how FTO gene variants contribute to obesity. It is conceivable that these polymorphisms lead to an altered gene expression of FTO , but no consistent data are available supporting this thesis so far.
In order to identify the molecular functions and signalling pathways of FTO in the hypothalamus and peripheral cells, for example, in adipocytes, tissue specifi c knock-out and overexpression of FTO would be needed. Here, proliferation or metabolic parameters like lipogenesis and glucose uptake could be assayed. Despite the fact that FTO is clearly associated with obesity, its genetic contribution to BMI is just 1 % . However, the population attributable risk of the SNP rs9939609 for overweight and obesity is 12.7 and 20.4 % [3] , indicating the substantial role in the predisposition to obesity. The further characterisation of the functional central and peripheral role of FTO in body weight regulation will be the basis for specifi c prevention or new treatment options. However, loss of FTO activity leads to severe developmental defects, limiting a therapeutic approach of targeting FTO in pharmacologic obesity treatment. Finally, the question if FTO is benefi cial or adverse concerning the development of obesity cannot be fully answered. Based on the latest studies, it is responsible for the predisposition to obesity and obesity-related disorders. On the other hand, it is essential for the normal central nervous and cardiovascular development in humans. Further studies will show if the fi ndings in mice models are transferable to the human metabolism.
